SARS-CoV-2 infection reduces human nasopharyngeal commensal microbiome with inclusion of pathobionts

Abstract

The microbiota of the nasopharyngeal tract (NT) play a role in host immunity against respiratory infectious diseases. However, scant information is available on interactions of SARS-CoV-2 with the nasopharyngeal microbiome. This study characterizes the effects of SARS-CoV-2 infection on human nasopharyngeal microbiomes and their relevant metabolic functions. Twenty-two (n = 22) nasopharyngeal swab samples (including COVID-19 patients = 8, recovered humans = 7, and healthy people = 7) were collected, and underwent to RNAseq-based metagenomic investigation. Our RNAseq data mapped to 2281 bacterial species (including 1477, 919 and 676 in healthy, COVID-19 and recovered metagenomes, respectively) indicating a distinct microbiome dysbiosis. The COVID-19 and recovered samples included 67% and 77% opportunistic bacterial species, respectively compared to healthy controls. Notably, 79% commensal bacterial species found in healthy controls were not detected in COVID-19 and recovered people. Similar dysbiosis was also found in viral and archaeal fraction of the nasopharyngeal microbiomes. We also detected several altered metabolic pathways and functional genes in the progression and pathophysiology of COVID-19. The nasopharyngeal microbiome dysbiosis and their genomic features determined by our RNAseq analyses shed light on early interactions of SARS-CoV-2 with the nasopharyngeal resident microbiota that might be helpful for developing microbiome-based diagnostics and therapeutics for this novel pandemic disease.

Differential gene expression profiling reveals potential biomarkers and pharmacological compounds against SARS-CoV-2: Insights from machine learning and bioinformatics approaches

“…COVID-19 diagnosis, laboratory testing, and treatment in this cohort have been previously described ( 30 ). Patients with confirmed COVID-19 were classified as having mild/moderate (MM) or severe/critical (SC) disease based on symptomatology ( 22 ).…”

Gut dysbiosis and long COVID‐19: Feeling gutted

“…Emerging evidence has suggested that the pathology of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) may in part be explained by microbial species, 1 contributing to the inflammatory phenotype commonly seen in patients with coronavirus disease (COVID‐19). 2 , 3 Indeed, dysbiosis of the gut microbiota has been associated with poor clinical outcomes in mechanically ventilated COVID‐19 patients. Specifically, Wu et al observed elevated Granulicatella and Rothia mucilaginosa in the gut microbiome of COVID‐19 hospitalized patients when compared to healthy individuals.…”

Unlocking the Potential of the Human Microbiome for Identifying Disease Diagnostic Biomarkers

“…Coronaviruses [206][207][208] Depression [209,210] Diabetes [211,212] Diarrheal Diseases [213][214][215] Epilepsy [216,217] Fibromyalgia Syndrome [218,219] Fungal Infections [220] Headache Disorders [221] HIV and AIDS [222,223] Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) [224,225] Irritable Bowel Syndrome [226,227] Lung Cancer [228,229] Melanoma [230,231] Metabolic Syndrome [232,233] Multidrug-Resistant Bacterial Infections [234,235] Multiple Sclerosis [236,237] Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome [238,239] Neurologic Cancer [240,241] Nonalcoholic Fatty Liver Disease [242,243] Obesity [244,245] Pain [246,247] Pancreatic Cancer [248,249] Parkinson's Disease [250,…”